Enhanced Oral Absorption of Ibandronate via Complex Formation with Bile Acid Derivative
- 1 February 2013
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (2) , 341-346
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Efficacy of Bisphosphonates in Reducing Fracture Risk in Postmenopausal OsteoporosisThe American Journal of Medicine, 2009
- Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacyOsteoporosis International, 2008
- Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO)Current Medical Research and Opinion, 2005
- Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trialsClinical Therapeutics, 2004
- Ibandronate: A Clinical Pharmacological and Pharmacokinetic UpdateThe Journal of Clinical Pharmacology, 2004
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosingOsteoporosis International, 2004
- Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studiesBritish Journal of Cancer, 2004
- Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone diseaseAnnals of Oncology, 1999
- BM 21.0955, a potent new bisphosphonate to inhibit bone resorptionJournal of Bone and Mineral Research, 1991